Clinical trialNCT06528301RecruitingPhase 1Interventional

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

SponsorUmoja BiopharmaEnrollment106Chronic Lymphocytic Leukemia (CLL)Lymphoma, B-CellLymphoma, Large B-Cell, Diffuse (DLBCL)Lymphoma, Non-Hodgkin (NHL)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Luke Walker, MD
Umoja Biopharma
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Cameron Turtle, MBBS, PhD
Recruiting
St. Vincent'S Hospital Melbourne
Fitzroy, Victoria, Australia
Matthew Ku, MD
Recruiting

United States

City of Hope
Duarte, California, United States
Tanya Siddiqi, MD
Not, yet, recruiting
the David and Etta Jonas Center for Cellular Therapy
Chicago, Illinois, United States
Michael Bishop, MD
Recruiting
Washington University School of Medicine/siteman Cancer Center
St Louis, Missouri, United States
Zachary Crees, MD
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Matthew Lunning, D.O. F.A.C.P.
Recruiting
University of Cincinnatti Medical Center
Cincinnatti, Ohio, United States
Zulfa Omer, MD
Recruiting
Fred Hutch Cancer Center
Seattle, Washington, United States
Ajay Gopal, MD/FACP
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sirolimus →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Mar 2025
Primary completion: 31 Mar 2029
Completion: 31 Mar 2029
Last update posted: 17 Aug 2026
Registered enrollment: 106
Registry id: NCT06528301

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.